Open Nav

Dr. Mintz brings a wealth of experience to his role as Chief Medical Officer at Verax. He is former president of the AABB who served as a tenured professor of Pathology and Medicine at the University of Virginia as well as Vice Chair of Pathology.

He also served on the AABB's board of directors for nine years, and chaired and was a member of numerous AABB committees. Most recently, Dr. Mintz served as Director, Division of Hematology Clinical Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration.


White Papers & Commentaries

  • The Verax Platelet PGD Test - FDA cleared indications for use and what they mean for your institution

    The Verax Platelet PGD Test has a broad range of FDA clearances to address whatever platelet types you may transfuse and now includes a new clearance for single units of whole blood derived platelets. In this report, we will review the specifics of each cleared indication for use and what this can mean for blood bank and transfusion service policies and procedures in your institution.
    Read the White Paper
  • Platelet Transfusion Efficacy Following Pathogen Reduction Treatment: An Italian Randomized Controlled Trial

    This major new publication reviews the findings of an Italian multi-center randomized trial comparing pathogen reduced platelets produced by two different technologies to untreated platelets. While it could not draw concrete conclusions on non-inferiority, it did find statistically significant differences in terms of the need for additional PR platelets to be transfused compared to untreated platelets as well as increased red cell consumption.
    Read the White Paper
  • WHO publishes list of bacteria for which new antibiotics are urgently needed thereby highlighting the requirement for further vigilance for platelet transfusions

    In this commentary on the list of "priority pathogens" recently published by the WHO, the very real risk that they could play an increasing role as platelet contaminants is explored.
    Read the Commentary
  • Verax Pan Genera Detection (PGD) test for platelet screening: A 5-year retrospective analysis in a high-volume transfusion service

    The first in a series of key poster and presentation reviews from the 2016 AABB Annual meeting. In this poster, Bracey and colleagues address implementing PGD in a large transfusion service and report their multiyear experience with the test's low false positive rate.
    Read the Poster Review
  • Predicted costs of implementing PGD Testing and Pathogen Reduction in a Hospital Transfusion Service

    In this AABB Annual Meeting presentation, Sorkin and Jacobson assess the significant economic implications of the alternatives for meeting the likely requirements of pending FDA guidance to address the risk of bacterial contamination in platelets.
    Read the Presentation Review
  • PGD Testing All Platelets in a University Transfusion Service While Minimizing the Number of Tests Performed

    In this AABB Annual Meeting poster, Vauthrin and colleagues present the results of their experience performing the PGD test daily over a 2 year period observing a repeat rate of just 1.17 tests per platelet dose.
    Read the Poster Review
  • Implementing 7 Day Platelet Dating with the Platelet PGD® Test

    Hospitals and blood centers across the country are implementing 7-day platelet dating with the Platelet PGD Test in order to improve platelet availability, inventory management, and reduce wastage caused by outdating. This complete review of the topic offers a detailed how-to guide, resources and insights drawn from institutions' experiences as well as a review of the support available to aid in going live with 7-day platelet dating.
    Read the White Paper
  • Will pathogen reduction of blood components harm more people than it helps in developed countries?

    This recently published article in the journal Transfusion takes a critical look at the implications of pathogen reduced blood components and their potential impact on massively transfused patients. A review of the authors methodology and conclusions raises significant concerns regarding the implications for the broad use of pathogen reduced platelets and plasma with trauma and other massively transfused patient populations.
    Read the Article Review
  • FDA Draft Guidance: Recommendations for addressing bacterial contamination risk in platelets and pathway for immediate extension of platelet dating to 7 days

    The FDA recently published draft guidance outlining its recommendations for addressing the risk of bacterial contamination in platelets as well as outlining the currently available pathway to 7 day platelet dating. This review summarizes the salient issues in the guidance and offers suggestions for hospital and blood center decision makers to consider as they evaluate the implications of this guidance for their facilities.
    Read the White Paper
  • The Inadequacy Of Passive Surveillance To Detect Septic Transfusion Reactions From Platelet Transfusion

    Septic transfusion reactions resulting from the transfusion of bacterially contaminated platelet components are a potentially fatal hazard of platelet transfusion. A review of the recent literature reveals just how ineffective passive surveillance is at recognizing when they occur and points the way towards active surveillance through testing as a better approach.
    Read the White Paper
  • Safety and Efficacy of Seven Day Platelets

    Recent FDA product approvals and a pathway outlined in draft FDA guidance have allowed the reintroduction of seven day platelet dating in the United States. But just how safe and effective are seven day platelets?  A review of published in vitro and in vivo studies reveals the current consensus.
    Read the White Paper

Have a question or comment? Click here to contact me directly.

Learn more about

"I'm excited to work at Verax because the company shares my passion for patient safety and best transfusion practices. I'll use this blog to express my thoughts and views about current topics in transfusion medicine and how they may impact your transfusion service or blood bank."

- Paul D. Mintz, MD

Hot Topics

CMS issues reimbursement code Q9987 for testing for pathogens in platelets that can be used with the Platelet PGD Test
Learn More

Major new article assesses economic impact on hospitals of methods to address bacterial contamination in platelets
Learn More

FDA advises testing for Zika virus in all donated blood and blood components in the US
Learn More

Congressional Representatives call for broad Zika blood screening citing a cost of less than $10 per donor
Learn More

Major new publication of note: "Will pathogen reduction of blood components harm more people than it helps in developed countries?"
Learn More

First blood center in Texas initiates routine blood donor screening for Zika virus with new test under IND
Learn More

7 Day platelet dating added to 30th Edition of the AABB Standards for Blood Banks and Transfusion Services
Learn More

New Draft FDA Guidance recommends secondary testing with rapid tests and Safety Measure testing for 7-day dating
Learn More